Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
MADRIGAL PHARMACEUTICALS, INC. (MDGL)
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Dec-31-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 |
| | 10-Q | 10-Q | 8-K | 10-Q | 10-Q | 10-K | 10-Q | 10-Q |
| Revenues [+] | 0.0 | 0.0 | 70.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Royalties | | | 70.7 | | | | | |
| Cost of goods sold | 0.0 | 0.0 | 85.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | -14.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | | | -20.6% | | | | | |
| Selling, general and administrative [+] | 17.8 | 16.2 | 14.6 | 11.8 | 9.7 | 11.7 | 8.3 | 10.1 |
| General and administrative | 17.8 | 16.2 | 14.6 | 11.8 | 9.7 | 11.7 | 8.3 | 10.1 |
| Research and development | 68.6 | 62.2 | | 58.5 | 47.9 | 52.9 | 54.9 | 51.6 |
| Other operating expenses | | | 56.2 | | | | | |
| EBITDA [+] | -86.3 | -78.2 | | -70.2 | -57.5 | -64.5 | -63.1 | -61.7 |
| EBITDA growth | 23.0% | 36.1% | 32.3% | 13.8% | 8.7% | 8.5% | 7.5% | 22.8% |
| EBITDA margin | | | -120.6% | | | | | |
| Depreciation and amortization | 0.1 | 0.1 | | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| EBIT [+] | -86.5 | -78.3 | -85.3 | -70.3 | -57.6 | -64.6 | -63.2 | -61.7 |
| EBIT growth | 23.0% | 36.0% | 32.0% | 13.8% | 8.7% | 8.5% | 7.4% | 22.7% |
| EBIT margin | | | -120.6% | | | | | |
| Interest income, net [+] | 0.7 | 1.4 | -1.7 | -0.5 | 0.1 | 0.1 | 0.1 | 0.1 |
| Interest expense | 2.9 | 2.3 | 1.7 | 0.8 | | | | |
| Interest income | 3.6 | 3.8 | | 0.3 | 0.1 | 0.1 | 0.1 | 0.1 |
| Other income (expense), net | | 0.0 | 1.1 | | | 0.0 | | |
| Pre-tax income | -85.8 | -76.9 | -85.9 | -70.7 | -57.5 | -64.5 | -63.1 | -61.7 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -85.8 | -76.9 | -85.9 | -70.7 | -57.5 | -64.5 | -63.1 | -61.7 |
| Net margin | | | -121.4% | | | | | |
| |
| Basic EPS [+] | ($4.69) | ($4.23) | ($4.98) | ($4.14) | ($3.36) | ($3.78) | ($3.79) | ($3.72) |
| Growth | 13.3% | 25.7% | 31.8% | 11.2% | 1.4% | -1.2% | 1.1% | 17.1% |
| Diluted EPS [+] | ($4.69) | ($4.23) | ($4.98) | ($4.14) | ($3.36) | ($3.78) | ($3.79) | ($3.72) |
| Growth | 13.3% | 25.7% | 31.8% | 11.2% | 1.4% | -1.2% | 1.1% | 17.1% |
| |
| Shares outstanding (basic) [+] | 18.3 | 18.2 | 17.2 | 17.1 | 17.1 | 17.1 | 16.6 | 16.6 |
| Growth | 7.1% | 6.3% | 1.0% | 3.2% | 8.0% | 10.5% | 7.7% | 7.4% |
| Shares outstanding (diluted) [+] | 18.3 | 18.2 | 17.2 | 17.1 | 17.1 | 17.1 | 16.6 | 16.6 |
| Growth | 7.1% | 6.3% | 1.0% | 3.2% | 8.0% | 10.5% | 7.7% | 7.4% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|